ABO-203
/ Arbor Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
February 13, 2026
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=66 | Recruiting | Sponsor: Ruijin Hospital | Trial completion date: Dec 2027 ➔ Dec 2028 | Trial primary completion date: Nov 2026 ➔ Nov 2027
Trial completion date • Trial primary completion date • Immunology
November 18, 2025
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=66 | Recruiting | Sponsor: Ruijin Hospital | N=26 ➔ 66
Enrollment change • Immunology
September 16, 2025
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=26 | Recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology
December 26, 2024
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=26 | Not yet recruiting | Sponsor: Ruijin Hospital
New P1 trial • Immunology
July 18, 2025
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1 | N=56 | Recruiting | Sponsor: Ruijin Hospital
New P1 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 5
Of
5
Go to page
1